Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Expands By 65.0%

ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Rating) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 513,200 shares, an increase of 65.0% from the March 15th total of 311,000 shares. Based on an average daily trading volume, of 132,800 shares, the short-interest ratio is currently 3.9 days. Currently, 4.2% of the company’s stock are sold short.

A number of analysts recently commented on the company. TheStreet lowered ANI Pharmaceuticals from a “c-” rating to a “d+” rating in a report on Wednesday, March 30th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ANI Pharmaceuticals in a report on Wednesday, March 16th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, March 14th. Raymond James lowered their target price on ANI Pharmaceuticals from $65.00 to $47.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 16th. Finally, StockNews.com assumed coverage on ANI Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $56.67.

Shares of ANIP opened at $32.16 on Friday. The firm has a market cap of $555.40 million, a PE ratio of -9.90 and a beta of 1.18. The stock’s fifty day moving average price is $33.37 and its two-hundred day moving average price is $39.31. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.68 and a quick ratio of 2.74. ANI Pharmaceuticals has a 1 year low of $24.41 and a 1 year high of $60.23.

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) last released its quarterly earnings data on Tuesday, March 15th. The specialty pharmaceutical company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.31). ANI Pharmaceuticals had a negative net margin of 19.71% and a positive return on equity of 14.10%. The company had revenue of $60.93 million for the quarter, compared to the consensus estimate of $58.25 million. During the same quarter in the previous year, the firm posted $0.65 earnings per share. Sell-side analysts anticipate that ANI Pharmaceuticals will post 0.58 earnings per share for the current fiscal year.

In related news, CEO Nikhil Lalwani bought 7,224 shares of the business’s stock in a transaction that occurred on Monday, March 21st. The shares were bought at an average price of $27.69 per share, with a total value of $200,032.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Muthusamy Shanmugam bought 5,000 shares of the business’s stock in a transaction that occurred on Thursday, March 17th. The shares were bought at an average cost of $27.65 per share, for a total transaction of $138,250.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 17,224 shares of company stock worth $477,083. 27.20% of the stock is owned by insiders.

Several large investors have recently added to or reduced their stakes in ANIP. First Trust Advisors LP raised its stake in shares of ANI Pharmaceuticals by 1.2% during the 1st quarter. First Trust Advisors LP now owns 15,122 shares of the specialty pharmaceutical company’s stock valued at $1,067,000 after purchasing an additional 179 shares during the period. Parametric Portfolio Associates LLC raised its stake in shares of ANI Pharmaceuticals by 52.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 28,909 shares of the specialty pharmaceutical company’s stock valued at $1,013,000 after purchasing an additional 9,924 shares during the period. WINTON GROUP Ltd raised its stake in shares of ANI Pharmaceuticals by 7.9% during the 3rd quarter. WINTON GROUP Ltd now owns 7,788 shares of the specialty pharmaceutical company’s stock valued at $256,000 after purchasing an additional 569 shares during the period. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals during the 3rd quarter valued at $414,000. Finally, Deutsche Bank AG raised its stake in shares of ANI Pharmaceuticals by 45.1% during the 3rd quarter. Deutsche Bank AG now owns 192,474 shares of the specialty pharmaceutical company’s stock valued at $6,317,000 after purchasing an additional 59,862 shares during the period. Institutional investors own 53.51% of the company’s stock.

ANI Pharmaceuticals Company Profile (Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

Read More

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.